Viewing nowClopixol 75 mg (Clopidogrel Sulfate)
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Huons Life Science Co., Ltd.

MFDS item code 201207379 · Approved 2012.10.23 · Insurance code 052700100
Improvement of atherosclerotic symptoms; prevention of atherothrombotic and thromboembolic events associated with atrial fibrillation
This medication is used to improve symptoms related to atherosclerosis, such as ischemic stroke, myocardial infarction, and peripheral arterial disease. It also reduces the risk of cardiovascular events such as death, myocardial infarction, and stroke in patients with acute coronary syndrome, especially those with unstable angina or non-Q wave myocardial infarction undergoing medical treatment, coronary intervention, or coronary artery bypass surgery. Furthermore, in adult patients with atrial fibrillation who have one or more vascular risk factors and in whom anticoagulation with vitamin K antagonists is challenging and bleeding risk is low, it helps decrease the risk of stroke and thromboembolism. This medication improves the prevention and treatment of such cardiovascular diseases.
○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), initiate treatment on the first day with a loading dose of 300 mg of this medicine once daily, followed by a maintenance dose of 75 mg orally once daily. In this case, aspirin 75 ~ 325 mg should be coadministered with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. In this case, aspirin 75 ~ 100 mg should be coadministered with this medicine once daily. ○ Patients with renal impairment: There is limited treatment experience in patients with renal impairment. ○ Patients with hepatic impairment: There is limited treatment experience in patients with moderate hepatic disease and bleeding diathesis. This medicine may be administered with or without food.
This medication prevents platelets from aggregating, reducing blood clotting. Its efficacy may be diminished in individuals genetically impaired in the function of a specific enzyme (CYP2C19); in such cases, adjusting the therapeutic approach or switching to another medication may be necessary. Furthermore, co-administration with drugs that activate this enzyme may increase drug concentration, raising the risk of bleeding, so this combination is not recommended. Patients with allergies to this medication, severe bleeding, severely impaired liver function, breastfeeding women, and lactose intolerant patients should not take this medication. Particularly, those with allergies to soybean oil, soy, and peanuts should exercise caution when taking this medication. Patients at high risk for bleeding or those scheduled for surgery should consult a physician before taking this medication, and should seek immediate medical attention if bleeding symptoms occur. The risk of bleeding may increase when this medication is taken concurrently with other antiplatelet drugs. During treatment, bleeding may take longer to stop; if a bleeding area is present or bleeding continues, promptly inform healthcare professionals. Rarely, this medication may cause thrombocytopenic purpura (TTP), a serious blood disorder, so immediate treatment is warranted if symptoms such as thrombocytopenia, anemia, neurological symptoms, or fever occur. While taking this medication, side effects such as headache, dizziness, abdominal pain, diarrhea, and skin rashes may occur; if symptoms are severe, consult a physician. Elderly patients, as well as those with impaired renal or liver function, are at higher risk for bleeding and other side effects, necessitating additional caution during treatment. If pregnant or breastfeeding, consult a physician before taking this medication, as it may affect the fetus or infant. In cases of overdose, the risk of bleeding may significantly increase, and treatments such as platelet transfusions may be required. This medication has not been adequately studied for safety and efficacy in children and should be avoided in this population. During treatment, inform a physician or pharmacist before starting any new medications, and report the use of this medication prior to any surgical or dental procedures.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to safely preserve the medication's efficacy.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowClopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Huons Life Science Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Geonil Pharmaceutical Co., Ltd.
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Sama Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
(Co., Ltd.) Korea Pharma

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.